Austedo, Teva's bright spot as it executes turnaround, fails two Tourette's trials
It was all going so well. Last week, Teva investors saw the light at the end of the tunnel, after Israel’s largest drugmaker handsomely beat Wall Street sales expectations by $100 million — following years of decline, precipitated by falling revenue, legal costs and mounting debt.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.